| MeSH term | MeSH ID | Detail |
|---|---|---|
| Pain | D010146 | 64 associated lipids |
| Reperfusion Injury | D015427 | 65 associated lipids |
| Colitis | D003092 | 69 associated lipids |
| Stomach Ulcer | D013276 | 75 associated lipids |
| Alzheimer Disease | D000544 | 76 associated lipids |
| Diabetes Mellitus, Experimental | D003921 | 85 associated lipids |
| Brain Ischemia | D002545 | 89 associated lipids |
| Weight Gain | D015430 | 101 associated lipids |
| Glioma | D005910 | 112 associated lipids |
| Inflammation | D007249 | 119 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
2-arachidonoylglycerol
2-arachidonoylglycerol is a lipid of Glycerolipids (GL) class. 2-arachidonoylglycerol is associated with abnormalities such as Atherosclerosis, Heart Diseases, Inflammatory disorder, Colitis and Peripheral Neuropathy. The involved functions are known as Immunoreactivity, inhibitors, Stimulus, Esthesia and Signal Transduction. 2-arachidonoylglycerol often locates in Back, Presynaptic Terminals, Brain region, Blood and Body tissue. The associated genes with 2-arachidonoylglycerol are ADRBK1 gene, Homologous Gene, MGLL gene, PLA2G4A gene and peptide V. The related lipids are oleoylethanolamide, Lipopolysaccharides, Promega, stearic acid and 1-stearoyl-2-arachidonoylglycerol. The related experimental models are Knock-out.
Cross Reference
Introduction
To understand associated biological information of 2-arachidonoylglycerol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with 2-arachidonoylglycerol?
2-arachidonoylglycerol is suspected in Atherosclerosis, Heart Diseases, Sweet's Syndrome, Colitis, Dehydration, Diabetes and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 2-arachidonoylglycerol
PubChem Associated disorders and diseases
What pathways are associated with 2-arachidonoylglycerol
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with 2-arachidonoylglycerol?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with 2-arachidonoylglycerol?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with 2-arachidonoylglycerol?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with 2-arachidonoylglycerol?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with 2-arachidonoylglycerol?
Knock-out
Knock-out are used in the study 'Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.' (Walentiny DM et al., 2015), Knock-out are used in the study 'Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).' (Navia-Paldanius D et al., 2012) and Knock-out are used in the study 'Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action.' (Viader A et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with 2-arachidonoylglycerol
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Lourbopoulos A et al. | Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis. | 2011 | Brain Res. | pmid:21406188 |
| Yamaguchi T et al. | Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice. | 2001 | Brain Res. | pmid:11478928 |
| Doenni VM et al. | Deficient adolescent social behavior following early-life inflammation is ameliorated by augmentation of anandamide signaling. | 2016 | Brain Behav. Immun. | pmid:27453335 |
| Mecha M et al. | Endocannabinoids drive the acquisition of an alternative phenotype in microglia. | 2015 | Brain Behav. Immun. | pmid:26086345 |
| Centonze D et al. | The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. | 2007 | Brain | pmid:17626034 |
| Mulder J et al. | Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. | 2011 | Brain | pmid:21459826 |
| Ryberg E et al. | The orphan receptor GPR55 is a novel cannabinoid receptor. | 2007 | Br. J. Pharmacol. | pmid:17876302 |
| Chicca A et al. | The antinociceptive triterpene β-amyrin inhibits 2-arachidonoylglycerol (2-AG) hydrolysis without directly targeting cannabinoid receptors. | 2012 | Br. J. Pharmacol. | pmid:22646533 |
| Lépicier P et al. | Endocannabinoids protect the rat isolated heart against ischaemia. | 2003 | Br. J. Pharmacol. | pmid:12813004 |
| Ho WS and Randall MD | Endothelium-dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2-arachidonoylglycerol. | 2007 | Br. J. Pharmacol. | pmid:17245358 |
| Guindon J and Hohmann AG | A physiological role for endocannabinoid-derived products of cyclooxygenase-2-mediated oxidative metabolism. | 2008 | Br. J. Pharmacol. | pmid:18297102 |
| Hu SS et al. | Prostaglandin E2 glycerol ester, an endogenous COX-2 metabolite of 2-arachidonoylglycerol, induces hyperalgesia and modulates NFkappaB activity. | 2008 | Br. J. Pharmacol. | pmid:18297109 |
| Mukhopadhyay P et al. | CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model. | 2010 | Br. J. Pharmacol. | pmid:20590569 |
| Gutierrez-Lopez MD et al. | Involvement of 2-arachidonoyl glycerol in the increased consumption of and preference for ethanol of mice treated with neurotoxic doses of methamphetamine. | 2010 | Br. J. Pharmacol. | pmid:20590579 |
| Solinas M et al. | The endocannabinoid system in brain reward processes. | 2008 | Br. J. Pharmacol. | pmid:18414385 |
| Kerr DM et al. | The monoacylglycerol lipase inhibitor JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action. | 2013 | Br. J. Pharmacol. | pmid:23043675 |
| Liao HT et al. | Capsaicin in the periaqueductal gray induces analgesia via metabotropic glutamate receptor-mediated endocannabinoid retrograde disinhibition. | 2011 | Br. J. Pharmacol. | pmid:21232043 |
| Bisogno T et al. | A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol with potential anti-obesity effects. | 2013 | Br. J. Pharmacol. | pmid:23072382 |
| Ghafouri N et al. | Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol. | 2004 | Br. J. Pharmacol. | pmid:15492019 |
| Guindon J et al. | The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors. | 2007 | Br. J. Pharmacol. | pmid:17179944 |